ProCE Banner Activity

Evidence for Use of Finerenone in T2D-associated CKD

Clinical Thought

Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP, summarizes key findings that underpin the use of finerenone in patients with diabetic kidney disease.

Released: August 04, 2022

Expiration: August 03, 2023

No longer available for credit.

Share

Faculty

Joshua J. Neumiller

Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP

Vice Chair & Allen I. White Distinguished Professor
Department of Pharmacotherapy
College of Pharmacy and Pharmaceutical Sciences
Washington State University
Spokane, Washington

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported by independent educational grants from

Bayer HealthCare Pharmaceuticals Inc.

Boehringer Ingelheim and Eli Lilly

Faculty Disclosure

Primary Author

Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP

Vice Chair & Allen I. White Distinguished Professor
Department of Pharmacotherapy
College of Pharmacy and Pharmaceutical Sciences
Washington State University
Spokane, Washington

Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP: consultant/advisor/speaker: Bayer, Dexcom, Novo Nordisk, Sanofi.